Abstract #0402

Incidence of Nephrogenic Systemic Fibrosis (NSF) in Dialysis Patients Receiving Either a Standard or a High-Relaxivity Gadolinium Chelate Contrast Agent: A Single Center Study

Saravanan Kokila Krishnamoorthy¹, Diego Martin¹, Khalil Nabeel Salman¹, Bobby Kalb¹, John Carew², Philip Andrew Martin³, Kenneth Kokko⁴, Christian Larsen⁵, Thomas Pearson⁵

¹Department of Radiology, Emory University, Atlanta, GA, USA; ²Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA; ³University of West Georgia, Carrollton, GA; ⁴Department of Medicine, Emory University, Atlanta, GA, USA; ⁵Department of Surgery, Emory University, Atlanta, GA, USA

Retrospective single center study measuring the incidence of Nephrogenic Systemic Fibrosis (NSF) in dialysis patients who were administered either gadodiamide or gadobenate dimeglumine. Mean cumulative dose of gadodiamide was 0.16 mmol/kg in 312 patients and 8 (2.6%) developed NSF. Mean cumulative dose of gadobenate dimeglumine was 0.11 mmol/kg in 603 patients and none developed NSF. The cause for this difference is not determined definitively but our results show that a change to a low dose higher relaxivity gadolinium chelate can significantly reduce NSF incidence and that the incidence in dialysis patients is less than 1 in 603 in our patients.